Abbott to Distribute Celera's KIF6 Test in EU | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Celera today announced that Abbott has licensed exclusive distribution rights to the firm's CE-marked KIF6 diagnostic test for use on Abbott's m2000 instrument system in the European Union and other areas that recognize the CE mark.

Under the four-year deal, Celera will manufacture the test, which Abbott will distribute in certain markets worldwide, but excluding the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.